Design and discovery of 1,3-benzodiazepines as novel dopamine antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 5218-5221

  Zhu, Zhaoning ^a   Sun, Zhong Yue ^a   Ye, Yuanzan ^a   McKittrick, Brian ^a   Greenlee, William ^a   Czarniecki, Michael ^a   Fawzi, Ahmad ^a   Zhang, Hongtao ^a   Lachowicz, Jean E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benzodiazepine; D1 receptor antagonist; Dopamine

Indexed keywords

1,3 BENZODIAZEPINE DERIVATIVE; 2 AMINOBENZODIAZEPINE DERIVATIVE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENZODIAZEPINE DERIVATIVE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DOPAMINERGIC SYSTEM; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GEOMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

BENZAZEPINES; BENZODIAZEPINES; DOPAMINE ANTAGONISTS; DRUG DESIGN; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68349131456     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.012     Document Type: Article

References (26)

1. Schultz W. Annu. Rev. Neurosci. 30 (2007) 259
2. Olver J.S., O'Keefe G., Jones G.R., Burrows G.D., Tochon-Danguy H.J., Ackermann U., Scott A., and Norman T.R. J. Affect. Disord. 114 (2009) 321
3. Tupala E., and Tiihonen J. Psychiat. Res.: Neuroimaging 162 (2008) 1
4. Noda Y., and Nabeshima T. Ann. N.Y. Acad. Sci. 1025 (2004) 62
5. Bourne J.A. CNS Drug Rev. 7 (2001) 399
6. Haney M., Ward A.S., Foltin R.W., and Fischman M.W. Psychopharmacology 155 (2001) 330
7. Nann-Vernptica E., Donny E.C., Bigelow G.E., and Walsh S.L. Psychopharmacology 155 (2001) 338
8. Astrup A., Greenway F.L., Ling W., Pedicone L., Lachowicz J., Strader C.D., and Kwan R. Obesity (Silver Spring) 15 (2007) 1717
9. 1a:. Chang W.K., Peters M., Fevig V.P., Kozlowski J.A., Zhou G., Lowe D.B., Guzik H., McQuade R.D., Duffy R., Coffin V., and Berger J.G. Bioorg. Med. Chem. Lett. 2 (1992) 399
10. 1b:. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., and Korduba C.A. J. Pharm. Exp. Ther. 226 (1983) 462
11. see also Ref. 2d.
12. Mottola D.M., Laiter S., Watts V.J., Tropsha A., Wyrick S.D., Nichols D.E., and Mailman R.B. J. Med. Chem. 39 (1996) 285
13. Wu W.-L., Burnett D.A., Spring R., Greenlee W.J., Smith M., Favreau L., Fawzi A., Zhang H., and Lachowicz J.E. J. Med. Chem. 48 (2005) 680
14. Baindur N., Tran M., Niznik H.B., Guan N.H.C., Seeman P., and Neumeyer J.L. J. Med. Chem. 35 (1992) 67
15. Oszczapowicz J., and Kuminska M. J. Chem. Soc., Perkin Trans. 2 (1994) 103
16. Hirt R.C., Halverson F., and King F.T. Spectrochim. Acta 15 (1959) 962
17. a of 10.4 in aqueous solution:. Hall H.K. J. Org. Chem. 29 (1964) 3135
18. Macromodel, Monte Carlo Conformational Search, BatchMin V9.1, MMFF94s, GBSA water solvation model, Schrödinger LLC, New York, NY.
19. Tedford C.E., Coffin V.L., Ruperto V., Cohen M., McQuade R.D., Johnson R., Kim H.-K., and Lin C.-C. Psychophamacology 113 (1993) 199
20. Tedford C.E., Ruperto V.B., Coffin V.L., Cohen M., Libonati M., and Barnett A. Drug Dev. Res. 26 (1992) 389
21. Tedford C.E., Ruperto V.B., and Barnett A. Drug Metab. Dispos. 19 (1990) 1152
22. Makosza M., Danikiewicz W., and Wojciechowski K. Liebigs Ann. Chem. (1988) 203
23. Chan D.M.T., Monaco K.L., Wang R.-P., and Winters M.P. Tetrahedron Lett. 39 (1998) 2933
24. 3OD, ppm), δ 7.58-7.63, m, 3H; 7.49-751, m, 2H; 7.27, s, 1H; 6.49, s, 1H; 3.76-3.77, m, 2H; 3.32-3.33, m, 2H; 2.20, s, 3H.
25. 6.
26. Combs A.P., Saubern S., Rafalski M., and Lam P.Y.S. Tetrahedron Lett. 40 (1999) 1623